Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial by EURO-SKI Investigators
www.thelancet.com/oncology   Published online May 4, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30192-X 1
Articles
Discontinuation of tyrosine kinase inhibitor therapy in 
chronic myeloid leukaemia (EURO-SKI): a prespecified interim 
analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele*, Johan Richter*, Joelle Guilhot*, Franz X Gruber, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J W M Janssen, Jiri Mayer, 
Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson-Strömberg, Joaquin Martinez-Lopez, Philippe Rousselot, Hanne Vestergaard, 
Hans Ehrencrona, Veli Kairisto, Katerina Machová Poláková, Martin C Müller, Satu Mustjoki, Marc G Berger, Alice Fabarius, 
Wolf-Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann†, Francois-Xavier Mahon†, on behalf of the EURO-SKI investigators‡
Summary
Background Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. 
Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define 
precise conditions for stopping treatment.
Methods In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 
61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any 
TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and 
had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free 
survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and 
assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors 
affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI 
therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or 
blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was 
done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and 
is registered with ClinicalTrials.gov, number NCT01596114.
Findings Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for 
eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 
27 months (IQR 21–34). Molecular relapse-free survival for these patients was 61% (95% CI 57–64) at 6 months and 
50% (46–54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while 
in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and 
heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase 
chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic 
myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 
405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio 
[OR] per year 1·14 [95% CI 1·05–1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04–1·23]; 
p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular 
response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line 
treatment, although the association was not significant (1·13 [0·98–1·29]; p=0·08). TKI discontinuation was associated 
with substantial cost savings (an estimated €22 million). No serious adverse events were reported.
Interpretation Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good 
molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who 
have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-
induced side-effects and reduce health expenditure.
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Introduction
Chronic myeloid leukaemia is a model disease for 
targeted therapy, characterised by the Philadelphia 
chromo some and its molecular counterpart, the 
BCR-ABL1 fusion gene.1 This specific leukaemic marker 
coding for a protein tyrosine kinase is considered the 
driver of the leukaemic process. This discovery led to the 
development of BCR-ABL1 tyrosine kinase inhibitors 
(TKIs), which improved the outcomes of patients with 
chronic myeloid leukaemia.2,3 The life expectancy of 
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patients with chronic myeloid leukaemia receiving TKI 
treatment is similar to that of the general population.4 
A substantial proportion of patients with chronic-phase 
chronic myeloid leukaemia achieve a deep molecular 
response on TKI therapy, which is defined by BCR-ABL1 
transcript levels measured with real-time (rt)PCR.5,6
The proof of concept for stopping TKI treatment came 
from the STIM1 trial,7 in which the criterion for stopping 
imatinib was undetectable BCR-ABL1 transcript for 2 years. 
Nearly 40% of patients in that trial were still in molecular 
remission (defined as a negative PCR result) after 3 years of 
imatinib discontinuation.7 The A-STIM study8 validated the 
loss of major molecular response (MMR) as a criterion for 
restarting TKI therapy. Other studies9,10 also confirmed the 
possibility of stopping TKI safely and successfully after 
therapy with second-generation TKIs, such as dasatinib 
and nilotinib. However, the exact conditions for stopping 
treatment are not yet defined because of small patient 
samples. As a result, some of the existing clinical treatment 
recom mendations have restricted TKI discontinuation to 
the clinical trial setting.11
To our knowledge, the European Stop Kinase Inhibitor 
(EURO-SKI) trial is the most extensive investigation of TKI 
discontinuation in a setting of decentralised, but stan-
dardised, molecular monitoring. We aimed to define the 
precise conditions for stopping treatment in patients with 
chronic myeloid leukaemia in deep molecular response.
Methods
Study design and participants
For this prospective, single-arm, open-label, non-
randomised trial, we enrolled patients with chronic 
myeloid leukaemia at 61 European centres in 11 countries 
(appendix p 7). Eligible patients were aged 18 years or 
older, had BCR-ABL1-positive chronic-phase chronic 
myeloid leukaemia, and were receiving first-line or 
second-line (because of toxicity with first-line TKI) 
treatment with any TKI or taking a TKI as part of a 
combination treatment. The minimum treatment 
duration with a TKI at any dose was 3 years, and the 
minimum duration of deep molecular response 
was 1 year. Deep molecular response was defined as 
detectable BCR-ABL1 (≤0·01% on the International 
Scale12) or undetectable BCR-ABL1 in samples with 
10 000 or more ABL1 transcripts or 24 000 or more GUS 
transcripts. To be included, patients had to have at least 
three PCR results showing deep molecular response 
within the year (give or take 2 months) before study entry 
and no results greater than 0·01% BCR-ABL during the 
same period. The date of the first recording of a deep 
molecular response and the dates of the last three 
recordings of deep molecular response before TKI 
discontinuation were mandatory.
We excluded patients with previous allogeneic stem-
cell transplantation, TKI failure (according to European 
LeukemiaNet [ELN] recommendations),13 or an active 
concomitant malignancy. A typical BCR-ABL1 transcript 
(majority e13a2 or e14a2) was necessary. Pre-treatment 
with interferon alfa, cytarabine, or hydroxycarbamide 
was allowed. Fertile women were included if they used 
an effective contraceptive. Additionally, patients had to 
have records on the date of diagnosis and values for the 
prognostic factors in the Sokal, Euro, and European 
Treatment and Outcome Study (EUTOS) scores (ie, age, 
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Research in context
Evidence before this study
We searched PubMed between Jan 1, 2004, and Dec 31, 2011, 
using the search term “stopping treatment in chronic myeloid 
leukemia” for English-language articles investigating imatinib 
discontinuation (the first tyrosine kinase inhibitor [TKI] used in 
chronic myeloid leukaemia). We identified additional relevant 
articles by examining the references of the articles identified in 
the literature search. Aside from several case reports and small 
pilot studies, only one prospective trial, the STIM trial, was 
published during that period. In that trial, 61% of patients had 
molecular recurrence after discontinuation of TKI treatment, 
mostly within 6 months. All patients who relapsed responded 
when imatinib was reintroduced as treatment. Prognostic 
factors in a multivariable analysis were TKI treatment duration 
and risk score at time of diagnosis. New definitions for 
molecular response were introduced in 2012. No other 
published studies using these new definitions had been 
published at the time of design of the EURO-SKI trial.
Added value of this study
In this multicentre, prospective study using standardised 
monitoring, we confirmed that patients with chronic myeloid 
leukaemia have good molecular relapse-free survival. To our 
knowledge, this study is the first to show that more exact criteria 
for stopping treatment could be defined using prognostic 
modelling to predict treatment-free remission at 6 months in a 
large cohort of patients. In multivariable analysis, treatment 
duration, interferon pre-treatment, and deep molecular response 
duration were significantly associated with the success of 
imatinib cessation. Deep molecular response duration had the 
largest effect on the success of treatment cessation, with a yearly 
increase of roughly 3% in the probability of staying in major 
molecular remission at 6 months over the observed time period. 
Considering only the drug price (before introduction of generic 
imatinib), discontinuation of imatinib therapy saved €22 million.
Implications of all the available evidence
Our results should help physicians in selecting patients with 
chronic myeloid leukaemia who are eligible for treatment 
discontinuation, and should be included in recommendations 
and guidelines on TKI discontinuation. Additionally, increasing 
the number of patients with chronic myeloid leukaemia who 
are recommended for TKI treatment discontinuation could 
have a large economic impact.
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palpable spleen size enlargement in cm below the costal 
margin, platelet count, and percentages of blasts, 
basophils, and eosinophils in peripheral blood). There 
were no restrictions on Eastern Cooperative Oncology 
Group performance status or lab oratory findings.
In agreement with each country’s public health code, 
the ethics committee at each centre or State Medical 
Chamber (for centres in Germany) approved the protocol. 
All patients were included after written informed consent 
was obtained. The full protocol of this trial is included in 
the appendix (pp 10–66).
Procedures
Molecular response was assessed with rtPCR at 
designated standardised EUTOS laboratories (each centre 
was assigned to one laboratory) and reported as the ratio 
of BCR-ABL1 to ABL1 or GUS on the International Scale. 
Molecular response assessment followed ELN recommen-
dations for BCR-ABL1 quantifi cation and scoring of deep 
molecular response,12,14 and was done once a month 
during the first 6 months after TKI dis continuation, every 
6 weeks until month 12, and then every 3 months for at 
least 3 years. Patients with a confirmed deep molecular 
response could stop TKI treatment immediately. 
Molecular recurrence was defined as loss of MMR, 
corresponding to expression of more than 0·1% BCR-ABL1 
transcripts at any time. For patients with loss of MMR, 
TKI treatment was restarted, ideally with the same TKI. 
Particularly for the primary endpoint, molecular results 
were centrally reviewed by members of the study steering 
committee.
Outcomes
The primary endpoint was molecular relapse-free survival, 
which was measured from the date of TKI discontinuation 
to the date of the first event (loss of MMR or death) or 
censoring. Observation time was censored on the date of 
re-initiation of therapy in patients who did not have 
molecular recur rence or on the date of the last molecular 
examination in all other patients without an event. 
We also assessed molecular relapse-free and treatment-
free survival as an unspecified, post-hoc end point. This 
endpoint differed from the primary endpoint in that 
restarting therapy without previous molecular recurrence 
was not censored, but was considered as an event. We 
decided to assess this endpoint because a patient might 
have restarted therapy before loss of MMR if they were 
perceived to be at a high risk of MMR loss or other events 
linked to withdrawal syndrome; this censoring could be 
considered as informative.
We assessed factors affecting MMR maintenance at 
6 months (prognostic analysis) and the cost impact of 
TKI discontinuation as secondary endpoints. Adverse 
events were assessed at each follow-up visit with the 
Common Toxicity Criteria. Serious adverse events were 
defined as loss of MMR, complete cytogenetic remission 
(>1% BCR-ABL1), or complete haematological remission 
(white blood cells <10 × 10⁹/L, platelets <450 × 10⁹/L, and 
disappearance of immature circulating cells and all signs 
and symptoms of the disease), or progres sion to 
accelerated-phase chronic myeloid leukaemia or blast 
crisis, all of which indicated progression of disease. 
In cases of death, the association of death with chronic 
myeloid leukaemia was assessed.
This Article presents the results of the prespecified 
interim analysis, which was planned for after the 6-month 
molecular relapse-free survival status was known for 
200 patients. None of these patients had to restart TKI 
treatment before molecular relapse. The secondary 
endpoints of overall survival, progression-free survival, 
patient-reported quality of life, and symptom burden over 
time will be reported in the final analysis, which is 
planned 3 years after the last patient was registered.
Statistical analyses
On the basis of previous results,15 we expected a 6-month 
molecular relapse-free survival of 40% or higher. Thus, 
the prespecified null hypothesis was 6-month molecular 
relapse-free survival of 40% or lower. If, at the interim 
analysis, at least 95 (47·5%) of 200 patients were still in 
MMR or better (ie, if the lower limit of the two-sided 
95% CI around 47·5% [40·4%] was above 40%), the null 
hypothesis would be discarded at the one-sided signifi-
cance level of 0·025 (type I error). With 200 patients, a 
true molecular-relapse free survival of at least 51% would 
give more than 80% power to reject the null hypothesis.
At the final analysis, the null hypothesis of the 3-year 
molecular relapse-free survival of being 35% or lower 
will be tested. If at least 197 (39·4%) of 500 patients are 
still in MMR or better, the lower confidence limit of the 
two-sided 95% CI around 39·4% will be higher than 
35% and the null hypothesis will be discarded at the one-
sided significance level of 0·025. The power to reject the 
null hypothesis will be higher than 80% if the true 
molecular relapse-free survival is at least 42%. A sample 
size of 500 patients would also allow investigation of 
about 25 potential prognostic factors, assuming that half 
of the patients lose their MMR status (relapse) during the 
3 years of follow-up and applying the rough estimate that 
ten events per investigated factor are needed. Although 
we had planned to recruit 500 patients, many investi-
gators and patients were interested in treatment 
discontinuation and on registering their data in the trial 
database to support research. Thus, more patients were 
recruited than planned.
We estimated molecular relapse-free survival and 
molecular relapse-free and treatment-free survival using 
the Kaplan-Meier method. We calculated the cumulative 
incidence of molecular recurrence by considering 
restarting treatment without evidence of molecular 
recurrence and death before molecular recurrence as 
competing events.16
We included all patients with follow-up data in the 
primary and safety analyses. We considered a patient to 
Universitätsklinikum Jena, 
Jena, Germany 
(Prof A Hochhaus MD); Institut 
für Medizinische 
Informationsverarbeitung, 
Biometrie und Epidemiologie, 
Ludwig-Maximilians-
Universität, Munich, Germany 
(M Pfirrmann PhD); and 
Bergonié Cancer Institute, 
Inserm Unit 916, University of 
Bordeaux, Bordeaux, France 
(Prof F-X Mahon MD)
Dr Franz X Gruber died in 
February, 2016
Correspondence to: 
Prof François-Xavier Mahon, 
Institut Bergonié, Bordeaux 
Cedex 33076, France 
francois-xavier.
mahon@u-bordeaux.fr
See Online for appendix
Articles
4 www.thelancet.com/oncology   Published online May 4, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30192-X
have been followed up if they had least one molecular 
result after treatment discontinuation. For all patients, a 
molecular follow-up of at least 6 months was aimed for, 
but a minimum follow-up was not required.
We used logistic regression analysis to investigate factors 
affecting MMR maintenance at 6 months. The learning 
sample in this analysis included all patients treated with 
first-line imatinib who had complete data on molecular 
relapse-free survival status at 6 months and all potential 
prognostic factors. Candidate prognostic factors were age 
at diagnosis and TKI discontinuation; sex; Sokal, Euro, 
EUTOS, and EUTOS long-term survival (ELTS) risk scores 
(or any variable part of any of those scores); previous 
interferon treatment; duration of TKI treatment; time to 
deep molecular response while receiving TKI treatment; 
and deep molecular response duration before TKI 
discontinuation. Values of all candidate variables had to be 
known at the date of TKI discontinuation. These variables 
were selected either because they were significantly 
associated with molecular relapse-free survival in previous 
studies15 or because they were suspected to be associated 
and had been documented in at least 90% of cases.
To investigate whether the best fit of a continuous 
variable in the logistic regression model was a straight 
line, fractional polynomials up to the second degree were 
considered as alternatives and investigated via a closed-
test procedure, as suggested by Royston and Sauerbrei.17 
The same principles were applied to the multiple 
regression analysis. Backward elimination was combined 
with an adaptive algorithm, which selected the best 
polynomial transformation for each continuous variable 
in turn to identify independent prognostic factors. 
Bootstrap resampling was done to assess the stability of 
the model.18 For the final model, the Hosmer and 
Lemeshow goodness-of-fit test was calculated.19 To aid in 
medical decision making, the linear predictor of the final 
model was intended to be categorised into risk groups. 
The classification was done with the minimum p value 
approach, with adjustment for multiple testing20 and 
assuming that the smallest group could contain at least 
20% of patients. Bootstrap resampling was applied to 
assess the stability of classification.18,20 The predictive 
quality of the classification was assessed in terms of 
sensitivity, specificity, and predictive values.
Before doing multiple regression analysis, the 
minimum p value approach was applied to interferon 
pre-treatment duration. The reason for this post-hoc 
analysis was that inclusion of patients with a longer 
period of interferon pre-treatment could constitute 
positive selection of patients who were able to stay in 
chronic phase also without TKI.
Prognostic results were validated in an independent 
sample. The independent validation sample consisted 
of all patients who had not been qualified for the 
learning sample because either their first-line TKI had 
not been imatinib or they did not have complete values 
for all candidate variables. After the identification of the 
final model in the learning sample, the prognostic 
quality of the same model was examined in the 
validation sample.
The cost analysis was done for patients pre-treated with 
imatinib. Months without TKI treatment were counted 
for each country separately. The assessment of the cost 
impact of TKI discontinuation included only patients 
who stopped imatinib. The analysis was done before 
generic approval in European countries. We accounted 
for differences in price between countries, and the mean 
cost of imatinib per month was used to estimate the 
saving per month for each patient.
Apart from the minimum p value approach, the 
significance level of the two-sided p values was 0·05 for 
all statistical tests.17 Analyses were done with SAS 
version 9.4, an SAS macro for multiple fractional 
polynomials, or RStudio version 1.0.136.
The study was registered with ClinicalTrials.gov, 
number NCT01596114.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of this 
Article. The corresponding author had full access to all of 
448 in learning sample 195 in validation sample
643 included in prognostic analysis
755 analysed for primary endpoint
758 had descriptive statistics available
821 registered
112 excluded (no data available at 
 6 months)
 3 excluded (inadequate molecular data)
33 excluded or protocol violation
30 data pending
868 patients pre-registered
47 excluded
46 screening failure*
1 no further information
Figure 1: Trial profile
*Deep molecular response not confirmed or other inclusion criteria no longer 
satisfied. 
Articles
www.thelancet.com/oncology   Published online May 4, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30192-X 5
the data and the final responsibility to submit for 
publication.
Results
Between May 30, 2012, and Dec 3, 2014, we screened 
868 patients with chronic-phase chronic myeloid leu-
kaemia at 61 European centres in 11 countries for 
eligibility (figure 1). 46 patients were excluded after 
screening and no further information was available 
for one patient. Thus, 821 patients were enrolled in the 
study. Descriptive characteristics were only available for 
758 patients at the time of the analysis (the cutoff date for 
data was Oct 11, 2016) because of exclusion criteria, and 
molecular analysis was only done for 755 patients because 
three patients had inadequate molecular data (figure 1).
Baseline characteristics and treatment information for 
758 patients is shown in table 1. 361 (48%) of 758 patients 
had previous treatment with hydroxycarbamide, 
interferon alfa, or both before TKI cessation. Of the 
362 patients who did not have pre-treatment, 338 received 
imatinib, six received dasatinib, and 18 received nilotinib 
as first-line TKI therapy. 66 (9%) of 758 patients had 
TKIs as part of a combination treatment: nine (1%) 
patients received imatinib in combination with ana-
grelide or hydroxy carbamide, 31 (4%) received imatinib 
and interferon alfa, 25 (3%) received imatinib and 
cytarabine, and one (<1%) received imatinib and 
pioglitazone.
123 (62% [95% CI 54–68]) of the first 200 evaluable 
patients were in MMR or better at 6 months, allowing 
the null hypothesis of 40% or lower molecular relapse-
free survival at 6 months to be rejected (p<0·0001).
Median follow-up of the 755 patients evaluable for 
molecular response was 27 months (IQR 21–34). 
373 (49%) patients lost MMR (two after restarting TKI 
therapy while in MMR), and the cumulative incidence of 
molecular recurrence was 39% (95% CI 35–42) at 
6 months (figure 2) and 49% (45–52) at 24 months. Loss 
of MMR occurred most frequently in the first 6 months 
after TKI discontinuation (in 297 [80%] of 373 patients), 
leading to a molecular relapse-free survival of 61% 
(95% CI 57–64) at 6 months (figure 3) and 50% (46–54) at 
24 months. Of these 755 patients, 371 (49%) lost MMR 
after TKI discontinuation, four (1%) died while in MMR 
for reasons unrelated to chronic myeloid leukaemia, and 
13 (2%) restarted TKI therapy while in MMR. When the 
13 TKI restarts before loss of MMR were also counted as 
an event, molecular relapse-free and treatment-free survival 
was 60% (56–63) at 6 months and 49% (45–52) at 
24 months (figure 3).
448 patients treated with imatinib qualified for 
prognostic modelling and were included in the learning 
sample. In this sample, duration of treatment with 
imatinib, deep molecular response duration, and 
interferon pre-treatment were significantly associated 
with MMR maintenance at 6 months after imatinib 
discontinuation (table 2). 
Patients pre-treated with interferon for 1·5 years or less 
were less likely than patients pre-treated for more than 
1·5 years to be in MMR 6 months after TKI discon-
tinuation: molecular relapse-free survival at 6 months 
was 86% (95% CI 72–95) in 43 patients who were pre-
treated for more than 1·5 years and 56% (51–60) in 
405 patients pre-treated for 1·5 years or less (OR 4·93 
[95% CI 2·04–11·94]; padjusted=0·00051). The probability of 
maintaining MMR at 6 months did not differ significantly 
Patients (n=758)
Sex
Female 362 (48%)
Male 396 (52%)
Age at diagnosis (years) 52 (41–60)
Age at TKI discontinuation (years) 60 (50–68)
Time from diagnosis to TKI discontinuation (years) 7·7 (5·1–10·4)
Duration of TKI therapy, years 7·5 (5·0–9·9)
Duration of DMR before TKI discontinuation (years) 4·7 (2·9–6·9)
Sokal score*
Low 259/584 (44%)
Intermediate 197/584 (34%)
High 128/584 (22%)
Euro score†
Low 239/547 (44%)
Intermediate 256/547 (47%)
High 52/547 (10%)
EUTOS score‡
Low 536/588 (91%)
High 52/588 (9%)
EUTOS long-term survival score*
Low 408/584 (70%)
Intermediate 141/584 (24%)
High 35/584 (6%)
Treatment before TKI 396 (52%)
Hydroxycarbamide 273 (36%)
Hydroxycarbamide and interferon alfa 66 (9%)
Interferon alfa 22 (3%)
Other 20 (3%)
Unknown 15 (2%)
First-line TKI
Imatinib 710 (94%)
Nilotinib 33 (4%)
Dasatinib 14 (2%)
Unknown 1 (<1%)
Second-line TKI
Imatinib 7/116 (6%)
Nilotinib 47/116 (41%)
Dasatinib 62/116 (53%)
Data are n (%), n/N (%), or median (IQR). The denominator is 758, unless 
otherwise stated. TKI=tyrosine kinase inhibitor. DMR=deep molecular response. 
EUTOS=European Treatment and Outcome Study. *Data were missing for 
174 patients. †Data were missing for 211 patients. ‡Data were missing for 
170 patients. 
Table 1: Patient characteristics
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between patients who were not pre-treated with interferon 
and those who were pre-treated for 1·5 years or less (1·32 
[0·64–2·72]; p=0·45). 43 patients who were pre-treated 
with interferon for more than 1·5 years were removed 
from the learning sample because they were likely to 
represent positive selection of patients and because it is 
currently uncommon for a patient to be pre-treated with 
interferon for this long before starting TKI therapy.
For the 405 patients remaining in the learning sample 
(of whom 180 [44%] had relapses), the association 
between deep molecular response duration before TKI 
discontinuation and probability of MMR at 6 months 
after TKI discontinuation remained significant (OR 1·13 
[95% CI 1·04 to 1·23]; p=0·0032). In combination with 
the intercept –0·38 (95% CI –0·82 to 0·06) estimated 
from the common logistic regression model, this OR 
translated into a yearly increase of about 3% in the 
probability of staying in MMR at 6 months over the 
observed range of deep molecular response durations. 
Table 3 shows the mean estimated and observed 
probabilities for 1-year intervals of deep molecular 
response duration.
Duration of imatinib treatment also remained signif-
icantly associated with probability of MMR at 6 months 
in the learning sample without patients pre-treated with 
interferon for more than 1·5 years (OR 1·14 [95% CI 
1·05–1·23]; p=0·0010). However, because deep molecular 
response duration before TKI discontinuation was part 
of duration of TKI treatment, these parameters were 
strongly correlated. Because of this collinearity, the 
variable time of TKI treatment before deep molecular 
response was investigated. The effect of this variable on 
molecular relapse-free survival at 6 months was not 
significant (OR 1·04 [95% CI 0·93–1·15]; p=0·50).
When considering all candidate variables for multi-
variable modelling, either deep molecular response 
duration before TKI discontinuation or duration of TKI 
treatment was significant. Because of their collinearity, 
only one of these variables could be kept in the model. 
The results of multivariable modelling with inclusion 
of deep molecular response duration before TKI 
discontinuation are shown in the appendix (p 9). Deep 
molecular response duration before TKI discontinuation 
and time of TKI treatment before deep molecular 
response showed a weak, negative correlation (r=–0·28). 
When time of TKI treatment before deep molecular 
response was added to deep molecular response duration 
before TKI discontinuation, only deep molecular res-
ponse duration before TKI discontinuation remained 
significant (p=0·0009 vs p=0·092 for time of TKI treat-
ment before deep molecular response). Looking at 
1000 bootstrap samples, deep molecular response 
duration before TKI discontinuation was significant in 
783 cases, and linear modelling was preferred over any 
fractional polynomial. The Hosmer-Lemeshow test did 
not indicate a poor goodness of fit (p=0·40).
The validation sample consisted of 195 patients 
(of whom 73 [37%] had relapses after 6 months). 
30 (15%) of these patients had received first-line nilotinib 
and 13 (7%) had received dasatinib. Type of first-line 
TKI did not significantly affect molecular relapse-free 
survival at 6 months (appendix p 9). Similar to the 
learning population, treatment duration with TKI, deep 
molecular response duration, and interferon pre-
treatment were significantly associated with molecular 
relapse-free survival at 6 months after TKI discontinuation 
(appendix p 9). Molecular relapse-free survival at 
6 months was 88% (95% CI 68–97) in 24 patients who 
had been pre-treated with interferon for more than 
1·5 years and 59% (51–67) in 171 patients pre-treated with 
interferon for 1·5 years or less (OR 4·85 [95% CI 
1·39–16·88]; p=0·013).
After the 24 patients who had been pre-treated with 
interferon for more than 1·5 years were excluded from 
Molecular recurrence
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TKI=tyrosine kinase inhibitor.
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the analysis, deep molecular response duration before 
TKI discontinuation in the remaining 171 patients (of 
whom 70 [41%] had relapses) had the same OR as in the 
learning sample, but the association was not significant 
(OR 1·13 [95% CI 0·98–1·29]; p=0·084). Duration of TKI 
treatment was also not significant (1·09 [0·98–1·21]; 
p=0·13).
Prognostic modelling in 405 patients in the learning 
sample led to two mutually exclusive univariate logistic 
models. Using the minimum p value approach for deep 
molecular response duration before TKI discontinuation, 
a cutoff of 3·1 years was observed (padjusted=0·0029), 
assuming that the smallest group contained at least 
20% of patients. This cutoff was confirmed with bootstrap 
resampling: in 1000 bootstrap samples, the cutoff of 
3·1 years was most frequently chosen (median 3·3 years 
[IQR 2·8–5·4]). For the 276 patients who had a deep 
molecular response while on treatment for more than 
3·1 years, the probability of maintaining MMR at 
6 months was 61% (95% CI 55–67; corresponding to the 
positive predictive value [PPV]), whereas it was 44% 
(35–53) for the 129 patients who had a deep molecular 
response for 3·1 years or less (OR 1·97 [95% CI 
1·29–3·00]). The negative predictive value (NPV) was 
56% (95% CI 47–65), sensitivity was 75% (68–80), and 
specificity was 40% (33–48).
For duration of imatinib treatment, 5·8 years 
(padjusted=0·00090) was identified as the cutoff. For the 
n (MMR)* β coefficient (SD) Odds ratio (95% CI) p value
Variables recorded at diagnosis
Age at diagnosis (years)† 448 (262) 0·001 (0·70) 1·00 (0·87–1·15) 0·99
Sex 448 (262) ·· ·· 0·73
Male 250 (148) Ref ·· ··
Female 198 (114) –0·07 (0·19) 0·94 (0·64–1·37) ··
Spleen size below costal margin (cm) 448 (262) 0·01 (0·02) 1·01 (0·96–1·05) 0·77
Platelet count (10⁹/L)‡ 448 (262) 0·18 (0·25) 2·20 (0·73–1·97) 0·48
Blasts in peripheral blood (%) 448 (262) –0·06 (0·05) 0·94 (0·86–1·03) 0·16
Eosinophils in peripheral blood (%) 448 (262) –0·07 (0·04) 0·94 (0·87–1·01) 0·08
Basophils in peripheral blood (%) 448 (262) 0·02 (0·03) 1·02 (0·96–1·09) 0·46
Sokal score 448 (262) ·· ·· 0·88
Low risk 216 (129) Ref ·· ··
Intermediate risk 172 (93) –0·10 (0·21) 0·91 (0·60–1·37) ··
High risk 70 (40) –0·11 (0·28) 0·90 (0·52–1·55) ··
Euro score 448 (262) ·· ·· 0·80
Low risk 208 (122) Ref ·· ··
Intermediate risk 199 (118) 0·03 (0·20) 1·03 (0·69–1·53) ··
High risk 41 (22) –0·20 (0·34) 0·82 (0·42–1·60) ··
EUTOS risk score 448 (262) ·· ·· 0·69
Low risk 414 (241) Ref ·· ··
High risk 34 (21) 0·15 (0·37) 1·16 (0·57–2·38) ··
EUTOS long-term survival score 448 (262) ·· .. 0·72
Low risk 329 (196) Ref .. ··
Intermediate risk 93 (52) –0·15 (0·24) 0·86 (0·54–1·37) ··
High risk 26 (14) –0·23 (0·41) 0·79 (0·36–1·77) ··
Variables recorded at TKI discontinuation
Age at stop of TKI (years)† 448 (262) 0·09 (0·07) 1·09 (0·95–1·26) 0·21
Interferon pre-treatment 448 (262) ·· ·· 0·0013
No 371 (204) Ref ·· ··
Yes 77 (58) 0·92 (0·28) 2·50 (1·43–4·36) ··
Duration of interferon pre-treatment (years) 448 (262) 0·32 (0·10) 1·38 (1·12–1·69) 0·0022
Duration of TKI treatment (years) 448 (262) 0·15 (0·04) 1·16 (1·08–1·25) <0·0001
DMR duration while receiving TKI (years) 448 (262) 0·15 (0·04) 1·16 (1·08–1·25) 0·00011
Time of TKI treatment before DMR (years) 448 (262) 0·02 (0·05) 1·02 (0·93–1·13) 0·66
All patients in the learning sample were treated with first-line imatinib. MMR=major molecular response. EUTOS=European Treatment and Outcome Study. TKI=tyrosine 
kinase inhibitor. DMR=deep molecular response. *Data are total number of individuals (number of individuals in MMR). †Age was divided by ten. ‡Platelet counts were 
divided by 1000.
Table 2: Variables affecting the probability of maintaining MMR 6 months after TKI discontinuation in the learning sample (n=448)
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267 patients who were treated with imatinib for more 
than 5·8 years, molecular relapse-free survival at 
6 months was 63% (95% CI 57–69; corresponding to the 
PPV), whereas it was 41% (33–50) for the 138 patients 
who were treated for up to 5·8 years (OR 2·41 [95% CI 
1·58–3·67]). The NPV was 59% (95% CI 50–67), 
sensitivity was 75% (95% CI 69–80), and specificity was 
45% (95% CI 38–53).
We tested the cutoffs for deep molecular response 
duration while receiving imatinib and duration of 
imatinib treatment in the 171 patients in the validation 
sample. For the 106 patients who had a deep molecular 
response for more than 3·1 years while receiving 
imatinib, molecular relapse-free survival at 6 months 
was 62% (95% CI 52–72; corresponding to the PPV), 
whereas it was 54% (41–66) for the 65 patients who had a 
deep molecular response of 3·1 years or less (OR 1·41 
[95% CI 0·76–2·65]; p=0·28). Thus, the NPV was 
46% (95% CI 34–59), sensitivity was 65% (95% CI 55–75), 
and specificity was 43% (95% CI 31–55).
For the 89 patients who were treated with imatinib for 
more than 5·8 years, molecular relapse-free survival at 
6 months was 63% (95% CI 52–73; corresponding to the 
PPV), whereas it was 55% (95% CI 43–66) for the 
82 patients treated with imatinib for 5·8 years or less 
(OR 1·40 [95% CI 0·76–2·57]; p=0·29). Thus, the NPV 
was 45% (95% CI 34–57), sensitivity was 55% (95% CI 
45–65), and specificity was 53% (95% CI 41–65).
596 patients with complete information about first-line 
imatinib treatment were considered assessable in the 
cost analysis. 279 patients restarted treatment after a 
median of 4 months (range 1–36), and 317 patients were 
still treatment-free at the last analysis, with a median 
time off treatment of 26 months (1–39). The total time off 
treatment was 1712 months in patients who were 
retreated and 8092 months in patients who stopped 
treatment. The mean cost of imatinib per month was 
€2262. Considering only the drug price, the total savings 
were €22 million. These savings were reduced by 
supplement ary investigations (eg, clinical visits, PCR 
analysis, examinations). We calculated that the median 
cost of a PCR test was €300. Within the first year, six 
additional tests per patient were necessary, resulting in 
costs of about €1·5 million. Because the cost of generic 
imatinib varies between countries, savings with generic 
imatinib were difficult to calculate, but continued to 
increase each month for the 317 patients who were off 
treatment at the time of writing.
No losses of complete haematological remission or 
progression due to accelerated-phase chronic myeloid 
leukaemia or blast phase were reported. 83 (11%) of 
755 patients were no longer in complete cytogenetic 
remission after loss of MMR, including 11 cases 
confirmed with cytogenetic evaluation. 13 (2%) patients 
restarted TKI without loss of MMR because of patient’s 
wish or treating physician’s decision. After restarting 
treatment, 321 (86%) of 373 patients had an MMR, of 
whom 302 (81%) were in deep molecular response. 
Median time to regaining MMR after resuming TKI 
therapy was 2·8 months (95% CI 2·7–2·9) and to 
regaining deep molecular response was 3·7 months 
(3·5–4·2). Because half of the patients had a follow-up of 
less than 1 year after restarting treatment (median 
11 months [IQR 8–15]), these results are preliminary.
Ten patients died for reasons unrelated to chronic 
myeloid leukaemia, including four who died while in 
MMR (due to myocardial infarction, lung cancer, renal 
cancer, and heart failure) and six (2%) who died in 
chronic-phase chronic myeloid leukaemia after loss of 
MMR and re-initiation of TKI therapy (due to myocardial 
infarction, cerebral infarction, pancreatic cancer, sept-
icaemia, pneumonia, and heart failure). The remaining 
378 patients were still alive and in MMR, including 
11 who had restarted TKI therapy and 367 who were not 
on treatment.
Adverse events were prospectively assessed (table 4). 
TKI withdrawal syndrome was noticed in 233 (31%) of 
758 patients, which was in line with a previous report.21 
Mostly transient, TKI withdrawal syndrome consisted of 
musculoskeletal or joint pain. 224 (30%) of 758 patients 
reported a grade 1–2 TKI withdrawal syndrome and 
nine (1%) patients reported a grade 3 TKI withdrawal 
syndrome (table 4) during the treatment period.
n/N* Estimated 
proportion 
without 
relapse (%)†
Observed 
proportion 
without relapse‡
Learning sample
1–2 14/44 45% 32% (19–48)
>2 to ≤3 39/72 49% 54% (42–66)
>3 to ≤4 28/55 51% 51% (37–65)
>4 to ≤5 35/60 55% 58% (45–71)
>5 to ≤6 28/42 58% 67% (50–80)
>6 to ≤7 25/48 61% 52% (37–67)
>7 to ≤8 27/34 64% 79% (62–91)
>8 to ≤9 10/21 66% 48% (26–70)
>9 19/29 70% 66% (46–82)
Validation sample
1–2 13/28 ·· 46% (28–66)
>2 to ≤3 17/31 ·· 55% (36–73)
>3 to ≤4 22/37 ·· 59% (42–75)
>4 to ≤5 11/17 ·· 65% (38–86)
>5 to ≤6 14/20 ·· 70% (46–88)
>6 to ≤7 9/15 ·· 60% (32–84)
>7 15/23 ·· 65% (43–84)
MMR=major molecular response. TKI=tyrosine kinase inhibitor. *Data are number 
of patients without relapse/total number of patients. †Mean proportion 
estimated for each individual deep molecular response duration from the logistic 
regression model. ‡Data are % (95% CI).
Table 3: Probability of maintaining MMR 6 months after TKI 
discontinuation, by duration of deep molecular response (years) before 
imatinib discontinuation
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Discussion
We found that cessation of TKI therapy in patients with 
chronic myeloid leukaemia in deep molecular response 
resulted in a molecular relapse-free survival of 
61% (95% CI 57–64) and a molecular relapse-free and 
treatment-free survival of 60% (56–63) at 6 months. 
Stopping TKI therapy appears feasible and safe when 
applying predefined criteria and decentralised, but 
standardised, molecular monitoring.
This study outlines important preconditions that can 
be used as guidance for defining stopping criteria. To our 
knowledge, this study is the first to show that more exact 
criteria for successful discontinuation of treatment could 
be defined with prognostic modelling to predict mol-
ecular relapse-free survival at 6 months in a large cohort 
of patients who discontinued imatinib. The large cohort 
of patients in the trial and the use of less stringent 
stopping criteria than used previously7–11,22,23 allowed the 
importance of duration of molecular remission to be 
validated before TKI discon tinuation was attempted.
Although our criteria for TKI discontinuation were less 
stringent (4-log10 reduction or lower) than those in the 
STIM1 study (patients with negative PCR results),7 the 
results of the two studies were similar, with most 
molecular recurrences occurring within the first 6 months 
after TKI discontinuation. Similarly, the criterion for 
retreatment in this study (loss of MMR at any timepoint) 
was less stringent than that in STIM1 (positivity for 
BCR-ABL1 transcript in two consecutive rtPCR assess-
ments, with a 1-log10 increase in the second assessment 
relative to the first, or loss of MMR in one assessment).7 
However, we confirmed and validated that loss of MMR 
is a safe criterion for TKI retreatment, as was previously 
shown in the A-STIM study.8 This criterion increases the 
patient population eligible for treatment discontinuation.
Because results from previous studies7,9,10,22,24 showed 
that 80% of molecular relapses occurred in the first 
6 months, we decided to assess factors affecting 
probability of maintaining MMR at 6 months. We found 
that duration of deep molecular response before TKI 
cessation was the most important factor affecting 
probability of remaining in MMR or better at 6 months 
after treatment discontinuation. Additionally, we found a 
roughly linear increase in the probability of molecular 
relapse-free survival per additional year in deep molecular 
response for patients treated with first-line imatinib.
The two components of total treatment time, time 
before deep molecular response and time after deep 
molecular response, are not independent of each other. 
Our results show the importance of deep molecular 
response duration in predicting molecular relapse-free 
survival. For duration of deep molecular response, both 
the learning and validation cohorts had the same 
OR of 1·13, with a wider confidence interval in the 
smaller validation sample (95% CI 0·98–1·29 vs 
1·04–1·23). Duration of deep molecular response was 
more important than total treatment time because it was 
significant on its own, whereas the first component of 
total treatment time, time before deep molecular 
response, was not significant. However, the two parts 
were negatively correlated, and the p value of time before 
deep molecular response was 0·092 in the multivariable 
analysis. The fact that the date of the first observation of 
Grade 1–2 Grade 3 Grade 4 Grade 5
Cardiovascular
Coronary disease (angina, myocardial 
infarction, ACS)
.. 2 (<1%) 4 (<1%) 2 (<1%)
Heart failure .. 2 (<1%) .. 2 (<1%)
Hypertension .. 3 (<1%) 1 (<1%) ··
Stroke or transient ischaemic attack .. 2 (<1%) 1 (<1%) 1 (<1%)
Arrhythmia .. 1 (<1%) .. ..
Deep vein thrombosis or thrombophlebitis .. 2 (<1%) .. ..
Respiratory
Cough or dyspnoea .. 3 (<1%) .. ..
Pneumonia .. 2 (<1%) .. 1 (<1%)
Oedema of throat .. 1 (<1%) .. ..
Renal and urinary tract
Pyelonephritis .. 1 (<1%) .. ..
Urinary retention .. 1 (<1%) .. ..
Hepatic and gastrointestinal tract
Hepatic abscess .. 1 (<1%) .. ..
Diverticulitis .. 1 (<1%) .. ..
Choledocholithiasis with biliary fistula .. 1 (<1%) .. ..
Intestinal disorder .. 1 (<1%) .. ..
Infectious
Septicaemia .. .. .. 1 (<1%)
Herpes zoster .. 1 (<1%) .. ..
Gluteal abscess .. 1 (<1%) .. ..
Vision
Chorioretinitis .. 1 (<1%) .. ..
Corneal ulcer .. 1 (<1%) .. ..
Diplopia .. 1 (<1%) .. ..
Cataract .. 1 (<1%) .. ..
CNS or psychiatric
Depression .. 1 (<1%) .. ..
Memory impairment .. 1 (<1%) .. ..
Vestibular neuropathy .. 1 (<1%) .. ..
Musculoskeletal pain*
Total 263 (35%) 11 (1%) .. ..
During treatment-free period 224 (30%) 9 (1%) .. ..
Other
Hypothyroidism .. 1 (<1%) .. ..
Spinal stenosis .. 1 (<1%) .. ..
Osteoporotic fracture .. 1 (<1%) .. ..
Alopecia .. 1 (<1%) .. ..
Data are number of events (%). The denominator is 758. All grade 3, 4, and 5 adverse events and all grade 1–2 events that 
were reported in more than 10% of patients in the study are shown. The total number of events might exceed the 
number of patients because patients might have experienced several events. ACS=acute coronary syndrome. *Includes 
musculoskeletal pain, bone or joint pain, arthralgia, myalgia, joint stiffness, lumbalgia, articular pain, muscular pain, neck 
pain, arthromyalgia, pain in both arms, pain in legs, and related terms.
Table 4: Adverse events
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deep molecular response was retrieved retrospectively 
and, therefore, might not always be exact is a limitation 
of this study. Because of these results, together with the 
surmised lack of exactness and for patient safety, total 
treatment time was also investigated and discussed.
The best cutoff for deep molecular response duration 
was defined as 3·1 years in the learning sample. Also 
significant, but of less importance, was the duration of 
imatinib therapy: more than 5·8 years of treatment 
before discontinuation increased the probability of 
molecular relapse-free survival at 6 months. Although 
these cutoffs could not be validated in the independent 
cohort, physicians should consider that the likelihood of 
treatment discontinuation succeeding might decrease or 
increase with otherwise shorter or longer treatment 
durations. Additionally, late relapses were not evaluated 
at this timepoint (planned after 3 years’ follow-up). 
Prospective evaluations in newly diagnosed patients, 
particularly those treated with second-generation TKI 
therapy, is needed for further insight.9,10
The STIM1 study7 found that duration of treatment was 
a significant predictive factor of molecular relapse-free 
survival. Treatment duration of at least 4·5 years was 
associated with a reduced risk of molecular recurrence; 
however, half of the patients in STIM1 had previously 
been treated with interferon, which was found to be an 
important factor in this study. By contrast with the STIM1 
study,7 we found that Sokal and EUTOS risk scores were 
not predictive of maintaining MMR.
The biological mechanisms of relapse after TKI 
discontinuation are not clearly understood, but they 
are an important and central part of chronic myeloid 
leukaemia research.25 An increased proportion of mature 
natural killer cells was associated with successful 
imatinib discontinuation in chronic myeloid leukae-
mia.26,27 Furthermore, expression of the CTLA-4 ligand, 
CD86, on plasmacytoid dendritic cells was shown to 
predict relapse risk after TKI discontinuation.28 Other 
mechanisms, such as aspects of stem cell biology, might 
also affect risk of relapse.
Because the life expectancy of patients with chronic 
myeloid leukaemia treated with TKI is now close to that of 
the general population, research on improving the 
management of this chronic disease is now focused on 
quality of life and economic aspects.29 TKI discontinuation 
has a large economic impact, with an estimated saving of 
€22 million alone for the participants in this study. The 
safety of TKI discontinuation has been an important issue. 
If discontinuation is done according to the procedures 
used in this trial, particularly with standard ised molecular 
monitoring of the major type of the BCR-ABL1 transcript, 
it is safe and practicable. Rapid reporting of PCR results 
ensures prompt TKI resumption upon molecular 
recurrence of the disease. Patients and physicians should 
also be aware of transient TKI with drawal syndrome.21,30
In summary, a discontinuation attempt could be 
suggested for patients fulfilling the criteria of this study 
because no safety issues were reported. To boost the 
likelihood of remaining recurrence-free, durations of 
deep molecular response and TKI treatment are 
important to take into account. For both parameters, a 
continuous, per-year increase in the probability of 
maintaining MMR at 6 months was observed in the 
learning cohort, with deep molecular response duration 
being more important than duration of treatment. These 
continuous increases were also observed in the validation 
cohort. Estimates of the probability of molecular relapse-
free survival with each additional year in deep molecular 
response before stopping imatinib could be used as 
guidance for physicians making decisions about 
individual patients. Physicians should weigh the side-
effects and costs of prolonged treatment against the 
probability of staying in MMR.
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